Sergio Traversa

CIK: 0001565832

Transaction Breakdown

Open Market Buys (P)13 (86.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (13.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RLMD

RELMADA THERAPEUTICS, INC.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

RLMD
RELMADA THERAPEUTICS, INC.
Sep 10, 2026
Purchase(P)
Direct
100K shares at avg. $4.10$410K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 9, 2026
Purchase(P)
Direct
100K shares at avg. $4.18$418K
RLMD
RELMADA THERAPEUTICS, INC.
Dec 15, 2025
Purchase(P)
Direct
27.5K shares at avg. $4.12$113K
RLMD
RELMADA THERAPEUTICS, INC.
Dec 12, 2025
Award(A)
Stock Appreciation Rights
Direct
1.2M shares-
RLMD
RELMADA THERAPEUTICS, INC.
Nov 5, 2025
Purchase(P)
Direct
272.5K shares at avg. $2.20$600K
RLMD
RELMADA THERAPEUTICS, INC.
Aug 28, 2025
Purchase(P)
Direct
56K shares at avg. $0.74$41K
RLMD
RELMADA THERAPEUTICS, INC.
Aug 27, 2025
Purchase(P)
Direct
129.5K shares at avg. $0.67$87K
RLMD
RELMADA THERAPEUTICS, INC.
Aug 26, 2025
Purchase(P)
Direct
80.5K shares at avg. $0.62$50K
RLMD
RELMADA THERAPEUTICS, INC.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
800K shares-
RLMD
RELMADA THERAPEUTICS, INC.
May 20, 2025
Purchase(P)
Direct
147.7K shares at avg. $0.56$82K
RLMD
RELMADA THERAPEUTICS, INC.
May 19, 2025
Purchase(P)
Direct
30K shares at avg. $0.50$15K
RLMD
RELMADA THERAPEUTICS, INC.
May 16, 2025
Purchase(P)
Direct
172.3K shares at avg. $0.45$77K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 11, 2024
Purchase(P)
Direct
51.4K shares at avg. $2.99$154K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 10, 2024
Purchase(P)
Direct
33K shares at avg. $2.75$91K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 9, 2024
Purchase(P)
Direct
55.6K shares at avg. $2.71$151K

		Type	Shares	Price		Ownership
Sep 10, 2026	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	100,000	$4.10	$410,000	Direct
Sep 9, 2026	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	100,000	$4.18	$418,000	Direct
Dec 15, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	27,500	$4.12	$113,300	Direct
Dec 12, 2025	RLMD RELMADA THERAPEUTICS, INC.	Award(A) Stock Appreciation Rights	1,198,000	-	-	Direct
Nov 5, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	272,500	$2.20	$599,500	Direct
Aug 28, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	55,976	$0.74	$41,422	Direct
Aug 27, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	129,455	$0.67	$86,735	Direct
Aug 26, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	80,545	$0.62	$49,938	Direct
Jun 26, 2025	RLMD RELMADA THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	800,000	-	-	Direct
May 20, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	147,686	$0.56	$82,246	Direct
May 19, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	30,000	$0.50	$14,994	Direct
May 16, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	172,314	$0.45	$77,472	Direct
Sep 11, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	51,407	$2.99	$153,707	Direct
Sep 10, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	33,014	$2.75	$90,789	Direct
Sep 9, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	55,579	$2.71	$150,619	Direct

1-15 of 15 transactions

About TRAVERSA SERGIO

TRAVERSA SERGIO (SEC CIK 0001565832) files insider reports with the SEC as Chief Executive Officer of RELMADA THERAPEUTICS, INC. (RLMD).

Signal8 holds 7 ownership filings by TRAVERSA SERGIO, all Form 4s, filed between Sep 11, 2024 and Sep 11, 2026. Those filings report 15 transactions, from Sep 9, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on TRAVERSA SERGIO's filings is in CORAL GABLES, FL.

Recent filings by TRAVERSA SERGIO

Sep 10, 2026: Open-market purchase of RLMD shares (Form 4, code P).
Sep 9, 2026: Open-market purchase of RLMD shares (Form 4, code P).
Dec 15, 2025: Open-market purchase of RLMD shares (Form 4, code P).
Dec 12, 2025: Grant or award of RLMD derivative securities (Form 4, code A).
Nov 5, 2025: Open-market purchase of RLMD shares (Form 4, code P).

Other insiders filing for RELMADA THERAPEUTICS, INC. (RLMD)

Shenouda Maged, Chief Financial Officer
Ence Chuck, CA and CO
Fedeli Fabiana, Director
GLASSPOOL JOHN, Director
Kelly Paul Edward, Director
CASAMENTO CHARLES J, Director

How to read Form 4 transaction codes